Kissei Pharmaceutical Co., Ltd. 4547
TSE · Japan · Health Technology
¥3,720.00-110.00 (-2.87%)
Market open· · JPY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · JPY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
The latest analyst update on Rigel Pharmaceuticals centers on a higher assessed fair value, which has moved from US$51.6 to US$61.2 per share in the current model. Analysts link this shift to how they view Veppanu in the U.S. and the ex U.S. potential of Rezlidhia under the Kissei partnership, with both products seen as key to supporting or challenging the new valuation. As you read on, you will see how to track this evolving narrative and what it could mean for your own view of Rigel...
Kissei Pharmaceutical (TSE:4547) cut its earnings guidance for the six months to September 2026 and the full year to March 2027 after TAVNEOS sales lagged expectations, affecting revenue forecasts and projected profitability. See our latest analysis for Kissei Pharmaceutical. The earnings guidance cut has come as Kissei Pharmaceutical’s share price sits at ¥4,160, with a 1-day share price return of 3.74% and a year-to-date share price return that is down 9.86%. The 5-year total shareholder...
Amgen Inc.’s (NASDAQ:AMGN) Japanese partner Kissei Pharmaceutical Co., Ltd. said it has started information-sharing activities in Japan, urging healthcare professionals to carefully evaluate the use of Tavneos (avacopan) following safety and regulatory concerns raised in the U.S. and Europe. Kissei Advises Doctors To Exercise Caution On Tavneos The company said physicians should avoid prescribing the drug to new patients and reassess continued treatment for current users while considering risks
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.